Join
Live feed
·
PRReleasevia Quantisnow
Kura Oncology Inc. logo

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
KURA· Kura Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KURA (Kura Oncology Inc.) and more on Quantisnow.